145 related articles for article (PubMed ID: 36924833)
1. Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data.
Yang CT; Yao WY; Ou HT; Kuo S
Diabetes Res Clin Pract; 2023 Apr; 198():110625. PubMed ID: 36924833
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney outcomes associated with GLP-1 receptor agonists versus long-acting insulins among type 2 diabetes patients requiring intensive glycemic control: a nationwide cohort study.
Peng ZY; Yang CT; Lin WH; Yao WY; Ou HT; Kuo S
Cardiovasc Diabetol; 2023 Oct; 22(1):272. PubMed ID: 37794465
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
Yang CY; Chen YR; Ou HT; Kuo S
Cardiovasc Diabetol; 2021 Jan; 20(1):21. PubMed ID: 33468131
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature review.
Peng ZY; Yang CT; Ou HT; Kuo S
Diabetes Obes Metab; 2022 Jul; 24(7):1328-1337. PubMed ID: 35373898
[TBL] [Abstract][Full Text] [Related]
5. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.
Morton JI; Marquina C; Shaw JE; Liew D; Polkinghorne KR; Ademi Z; Magliano DJ
Diabetologia; 2023 Apr; 66(4):642-656. PubMed ID: 36404375
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
7. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
Bai S; Lin C; Jiao R; Cai X; Hu S; Lv F; Yang W; Zhu X; Ji L
Eur J Intern Med; 2023 Mar; 109():79-88. PubMed ID: 36628824
[TBL] [Abstract][Full Text] [Related]
8. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Brunton SA; Wysham CH
Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
[TBL] [Abstract][Full Text] [Related]
10. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
11. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
Raya PM; Blasco FJA; Hunt B; Martin V; Thorsted BL; Basse A; Price H
Diabetes Obes Metab; 2019 Jun; 21(6):1349-1356. PubMed ID: 30740861
[TBL] [Abstract][Full Text] [Related]
13. Lower risks of cirrhosis and hepatocellular carcinoma with GLP-1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework.
Yang CT; Yao WY; Yang CY; Peng ZY; Ou HT; Kuo S
J Intern Med; 2024 Mar; 295(3):357-368. PubMed ID: 37994187
[TBL] [Abstract][Full Text] [Related]
14. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
[TBL] [Abstract][Full Text] [Related]
15. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Fonseca V; Umpierrez GE; Caramori ML; Joseph A; Lambelet M; Lawatscheck R; Bakris GL;
Diabetes Obes Metab; 2023 Feb; 25(2):407-416. PubMed ID: 36193847
[TBL] [Abstract][Full Text] [Related]
16. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
Longato E; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Nov; 20(1):222. PubMed ID: 34774054
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
19. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
Xu L; Zheng XQ; Liao XX
Prim Care Diabetes; 2022 Feb; 16(1):207-210. PubMed ID: 34953749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]